Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.32 | -0.28
Decreased by
-14.29%
|
Nov 10, 22 | -0.32 | -0.28
Decreased by
-14.29%
|
May 10, 22 | -0.26 | -0.33
Increased by
+21.21%
|
Mar 16, 22 | -0.22 | -0.40
Increased by
+45.00%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-3.54 M
Increased by
+11.55%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-2.62 M
Decreased by
-139.75%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-2.67 M
Decreased by
-192.34%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00 - | -7.83 M - |
Decreased by
N/A%
-
|
Jun 30, 21 | 0.00 - | -4.00 M - |
Decreased by
N/A%
-
|
Dec 31, 20 | 0.00 - | -1.09 M - |
Decreased by
N/A%
-
|
Jun 30, 20 | 0.00 - | -913.36 K - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.